Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiota and immune profiling of microbiota-humanised versus wildtype mouse models of hepatointestinal schistosomiasis.

Animal microbiome·2024
Same author

Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis.

Nature communications·2023
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Managing junctional haemorrhage in the combat environment.

BMJ military health·2020
Same author

Evaluation of a visual tool co-developed for training hospital staff on the prevention and control of the spread of healthcare associated infections.

Infection, disease & health·2019

Related Experiment Video

Updated: Jul 11, 2026

Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)
14:15

Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)

Published on: June 18, 2012

Sirolimus-tacrolimus combination immunosuppression.

V C McAlister, Z Gao, K Peltekian

    Lancet (London, England)
    |February 9, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Organ transplant recipients on sirolimus and low-dose tacrolimus showed low rejection rates and good graft function. This combination therapy proved effective and safe, avoiding significant drug toxicity in liver, kidney, and pancreas transplant patients.

    More Related Videos

    Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
    07:49

    Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

    Published on: April 13, 2015

    Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
    08:41

    Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

    Published on: June 7, 2017

    Related Experiment Videos

    Last Updated: Jul 11, 2026

    Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)
    14:15

    Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)

    Published on: June 18, 2012

    Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
    07:49

    Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

    Published on: April 13, 2015

    Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
    08:41

    Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

    Published on: June 7, 2017

    Area of Science:

    • Nephrology
    • Hepatology
    • Transplant Surgery

    Background:

    • Immunosuppression is crucial after organ transplantation to prevent rejection.
    • Calcineurin inhibitors like tacrolimus are standard but associated with toxicity.
    • Novel immunosuppressive strategies are needed to improve long-term outcomes.

    Purpose of the Study:

    • To evaluate the efficacy and safety of sirolimus combined with low-dose tacrolimus in transplant recipients.
    • To assess the rates of graft rejection and graft function in this patient cohort.

    Main Methods:

    • A retrospective analysis of 32 patients who received liver, kidney, or pancreas transplants.
    • Patients were treated with a combination of sirolimus and low-dose tacrolimus.
    • Outcomes included rejection rates, graft function, and adverse events.

    Main Results:

    • A low rate of acute rejection was observed in the study group.
    • Excellent graft function was maintained throughout the follow-up period.
    • No significant drug-related toxic effects were reported, indicating good tolerability.

    Conclusions:

    • Sirolimus combined with low-dose tacrolimus is an effective immunosuppressive regimen for liver, kidney, and pancreas transplant recipients.
    • This combination therapy offers a favorable safety profile with minimal toxicity.
    • The findings support the use of this regimen to improve transplant outcomes.